Related Experiment Video
Updated: May 24, 2026

Broth Microdilution In Vitro Screening: An Easy and Fast Method to Detect New Antifungal Compounds
Published on: February 14, 2018
Empiric antifungal therapy and outcomes in extremely low birth weight infants with invasive candidiasis
Rachel G Greenberg1, Daniel K Benjamin, Marie G Gantz
1Department of Pediatrics, Duke University, Durham, NC, USA.
Insights
Empiric antifungal therapy in premature infants with invasive candidiasis was linked to better survival without neurodevelopmental impairment (NDI). Further research is recommended to confirm these findings.
Area of Science:
- Neonatal Medicine
- Infectious Diseases
- Pharmacology
Background:
- Invasive candidiasis poses a significant threat to premature infants.
- Early intervention with antifungal therapy is crucial for improving outcomes.
Purpose of the Study:
- To evaluate the impact of empiric antifungal therapy on outcomes in premature infants with invasive candidiasis.
- To assess the association between empiric antifungal treatment and survival, infection clearance, and major morbidities.
Main Methods:
- Cohort study of very low birth weight infants (≤ 1000 g) with positive Candida cultures.
- Defined empiric antifungal therapy as administration on or before the first positive culture.
- Used propensity score-stratified Cox and logistic regression models to analyze outcomes.
Main Results:
- Invasive candidiasis occurred in 136 infants.
- Empiric antifungal therapy was associated with a lower incidence of death or neurodevelopmental impairment (NDI) (50% vs. 64%).
- No significant differences were observed for individual outcomes or other combined outcomes.
Conclusions:
- Empiric antifungal therapy showed a positive association with survival without NDI in premature infants.
- A prospective randomized trial is needed to validate this therapeutic strategy.
Objective:
To assess the impact of empiric antifungal therapy for invasive candidiasis on subsequent outcomes in premature infants.
Study Design:
This was a cohort study of infants with a birth weight ≤ 1000 g receiving care at Neonatal Research Network sites. All infants had at least one positive culture for Candida. Empiric antifungal therapy was defined as receipt of a systemic antifungal on the day of or the day before the first positive culture for Candida was drawn. We created Cox proportional hazards and logistic regression models stratified on propensity score quartiles to determine the effect of empiric antifungal therapy on survival, time to clearance of infection, retinopathy of prematurity, bronchopulmonary dysplasia, end-organ damage, and neurodevelopmental impairment (NDI).
Results:
A total of 136 infants developed invasive candidiasis. The incidence of death or NDI was lower in infants who received empiric antifungal therapy (19 of 38; 50%) compared with those who had not (55 of 86; 64%; OR, 0.27; 95% CI, 0.08-0.86). There was no significant difference between the groups for any single outcome or other combined outcomes.
Conclusion:
Empiric antifungal therapy was associated with increased survival without NDI. A prospective randomized trial of this strategy is warranted.
Related Concept Videos
Antifungal Agents
Fungal Phylum Microsporidia
Pharmacokinetics in Pediatric Patients: Drug Excretion
